Sign up to save your podcasts
Or
Share In spite of plummeting valuation, 23andMe still aims to pivot into biotech
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
In spite of plummeting valuation, 23andMe still aims to pivot into biotech
23andMe has seen its valuation plummet from $6 billion to close to zero, with the Nasdaq threatening to delist the company’s stock. Still, company leaders have high hopes for medical research and a pivot to biotech. Rolfe Winkler has been writing about what happened for The Wall Street Journal, and discussed the company’s financial woes and future roadmap with Marketplace’s Lily Jamali.
View all episodes
By Marketplace
4.5
12341,234 ratings
23andMe has seen its valuation plummet from $6 billion to close to zero, with the Nasdaq threatening to delist the company’s stock. Still, company leaders have high hopes for medical research and a pivot to biotech. Rolfe Winkler has been writing about what happened for The Wall Street Journal, and discussed the company’s financial woes and future roadmap with Marketplace’s Lily Jamali.
More shows like Marketplace Tech
View all
Science Friday
6,056 Listeners
Marketplace Morning Report
882 Listeners
Marketplace
8,644 Listeners
Planet Money
30,898 Listeners
Marketplace All-in-One
1,359 Listeners
Freakonomics Radio
32,202 Listeners
Hidden Brain
43,390 Listeners
The Uncertain Hour
2,168 Listeners
Make Me Smart
5,493 Listeners
Bold Names
1,443 Listeners
The Indicator from Planet Money
9,553 Listeners
This Is Uncomfortable
3,594 Listeners
Short Wave
6,248 Listeners
Marketplace Minute
163 Listeners
Million Bazillion
2,685 Listeners
How We Survive
1,322 Listeners
The Economics of Everyday Things
1,589 Listeners
Financially Inclined
82 Listeners
Everybody in the Pool
221 Listeners